Genesis raises $30 million in financing
The notes carry an annual interest rate of 6% and are convertible into shares of the company’s common stock at a conversion price of $0.20 per share. In
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.